Search Congress
Bills
40 shown of 58 matchesVeterans Health Administration Novel Therapeutics Preparedness Act
Strengthens Veterans Health Administration preparedness for novel therapeutics used in veterans health care delivery
Modern Authentication of Pharmaceuticals Act of 2025
Requires oral solid controlled substances to carry machine readable physical chemical identifiers for drug authentication beginning five years after enactment
To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
Nullifies the FDA's January 2023 mifepristone REMS changes and bars similar future changes to dispensing requirements for the abortion pill
Protecting Life from Chemical Abortions Act
Nullifies FDA changes to mifepristone dispensing rules, restricts loosening REMS protections, and generally bars abortion-related public health emergency declarations
Combating Illicit Xylazine Act
Establishes federal controls targeting illicit xylazine by treating it as a regulated drug trafficking substance
INSULIN Act of 2026
Establishes the INSULIN Act of 2026 as a Senate bill on insulin policy and regulation
Combating Illicit Xylazine Act
Regulates illicit xylazine under the Controlled Substances Act by placing it in schedule III, setting penalties, and preserving specified animal-use exemptions
Innovation in Pediatric Drugs Act of 2025
Expands FDA authority over pediatric studies for orphan drugs used in rare pediatric diseases and strengthens related research, enforcement, and reporting requirements
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Appropriates FY2026 funding for USDA, the Food and Drug Administration, rural development, nutrition assistance, and related agricultural agencies, while setting conditions on use of those funds
National Defense Authorization Act for Fiscal Year 2026
Sets FY2026 defense and national security policies and authorities for Defense Department programs, military construction, nuclear security, and related State Department, Coast Guard, and intelligence activities
Consolidated Appropriations Act, 2026
Funds multiple federal departments and agencies for the rest of FY2026, continues Homeland Security funding temporarily, and extends several expiring federal programs and authorities
Full-Year Continuing Appropriations and Extensions Act, 2025
Provides full-year FY2025 continuing appropriations for federal agencies and extends multiple expiring health and other federal programs and authorities through FY2025
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026
Extends continuing appropriations for agriculture, the legislative branch, and military construction and veterans affairs, while continuing related extensions for fiscal year 2026
Intelligence Authorization Act for Fiscal Year 2026
Authorize intelligence and intelligence-related activities and set fiscal year 2026 oversight and funding rules for U.S. intelligence programs
Continuing Appropriations and Extensions and Other Matters Act, 2026
Provides continuing fiscal year 2026 funding for federal agencies, permanently extends expanded health insurance tax credits, and extends several expiring programs and authorities
Continuing Appropriations and Extensions and Other Matters Act, 2026
Extends FY2026 federal funding through a short-term continuing resolution while permanently extending expanded health insurance premium tax credits and continuing several expiring programs
Continuing Appropriations Act, 2027
Continues FY2027 appropriations for federal agencies through early December 2026 or until regular appropriations are enacted, while extending several expiring programs and authorities
Continuing Appropriations and Extensions Act, 2027
Continues FY2027 funding for federal agencies through December 11, 2026 or until regular appropriations are enacted, while extending multiple expiring federal programs and authorities
Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026
Authorize FY2026 defense programs and military construction, set national security policy for the Department of Defense and related agencies, and speed defense acquisition delivery
National Defense Authorization Act for Fiscal Year 2026
Set FY2026 defense policy and authorize military programs, construction, and Department of Energy national security activities, including force levels, procurement, and defense oversight
Recognizing the history of the drug diethylstilbestrol and the harm it has caused, and for other purposes.
Recognizes the history of diethylstilbestrol and the harm the drug has caused to affected people
To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests", and for other purposes.
Prohibits federal funding to carry out or enforce the FDA laboratory developed tests rule treating certain tests as regulated medical devices
Prescription Freedom Act of 2025
Eliminates FDA authority to require prescription-only dispensing for most drugs while keeping that authority for drugs intended to terminate a pregnancy
Interagency Patent Coordination and Improvement Act of 2025
Establishes an interagency patent task force to coordinate USPTO and FDA work on patents for human drugs and biological products
SAFE Drugs Act of 2026
Increases oversight of drug compounding by tightening statutory limits on compounded copies of commercially available drugs and adding reporting and inspection requirements
Stop STALLING Act
Prohibits objectively baseless FDA citizen petitions used to delay competing drug approvals and treats them as unfair competition in the generic drug market
Mikaela Naylon Give Kids a Chance Act
Expand FDA authority over rare pediatric disease research by strengthening pediatric study enforcement, renewing pediatric incentives and funding, and clarifying orphan drug exclusivity rules
Over-the-Counter Monograph Drug User Fee Amendments
Reauthorizes the FDA over-the-counter monograph drug user fee program through FY2030 and updates fee amounts, deadlines, and eligible order requests
FDA Modernization Act 3.0
Require the FDA to issue an interim final rule updating investigational new drug regulations to use nonclinical testing terms instead of animal testing references
To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.
Allows FDA approval of certain later-filed generic drug applications when a first filer does not begin commercial marketing within the required timeframe
FDA Modernization Act 3.0
Require the FDA to issue an interim final rule updating investigational new drug regulations to use nonclinical testing terms instead of animal testing references
Biosimilar Red Tape Elimination Act
Eliminate regulatory requirements identified as red tape for biosimilar products
Pregnancy Is Not an Illness Act of 2025
Prohibit the FDA from treating pregnancy as an illness when approving or regulating abortion drugs, and void affected approvals including mifepristone
Prompt Approval of Safe Generic Drugs Act
Authorize FDA approval of certain generic drugs with labeling that omits patent- or exclusivity-protected safety information while still requiring safety information needed for safe use
Scientific EXPERT Act of 2025
Require the FDA to take part in externally led scientific meetings on rare disease drug development and use them to inform review of new drugs and biologics
Expedited Access to Biosimilars Act
Expand faster market entry for biosimilars by creating an expedited access pathway for those biologic products
Scientific EXPERT Act of 2025
Requires the FDA to take part in externally led scientific meetings on rare disease drug development and use a structured process to gather and report input from those meetings
Medication Affordability and Patent Integrity Act
Establishes medication affordability and patent integrity rules to curb patent abuse that can delay lower-cost drugs
Medical Device Electronic Labeling Act
Expands electronic labeling for all medical devices by allowing directions and warnings to be given digitally instead of only in physical form under specified conditions
SAVE Moms and Babies Act of 2025
Prohibits FDA approval of new abortion drugs and tightens dispensing and labeling limits on already approved pregnancy termination drugs